[at noodls] – Philadelphia, PA, Monday, March 18, 2013: Hemispherx Biopharma (NYSE MKT: HEB) announced its financial results for the fiscal year ended December 31, 2012. The net loss for 2012’s twelve month period (including … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here […]
[at noodls] – Hemispherx Biopharma Receives Complete Response Letter from FDA on Ampligen® New Drug Application for Chronic Fatigue Syndrome …Hemispherx will seek an End-of-Review Conference with the FDA Philadelphia, … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]
[at noodls] – Philadelphia, PA, Friday, December 21, 2012: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the Company or Hemispherx) today announced the outcome of the meeting of the Arthritis Advisory … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboardSee who Hemispherx is hiring next, click here to view […]
[at noodls] – HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2012 .. AMPLIGEN® NEW DRUG APPLICATION AND PRE-APPROVAL INSPECTION ARE TOP PRIORITIES…….This is an abstract of … moreView todays social media effects on HEBView the latest stocks trending across Twitter. Click to view dashboard […]
